Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...
Continuous process improvement can benefit all aspects of life — from personal New Year’s resolutions to complex drug development. In a world where two-thirds of planned improvement initiatives fail, ...
A new compound, called VU319, has delivered promising results in a Phase 1 trial for treating Alzheimer’s disease and other neudegenerative conditions. The corresponding study was published in ACS ...
Artificial intelligence is revolutionizing drug development, significantly reducing the time it takes to bring life-saving ...
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research.
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
In the increasingly complex healthcare realm, a regular flow of drug introductions offers potential benefits to millions of patients. However, the biotech and pharmaceutical companies that develop ...
The Congressional Budget Office (CBO) informs Congress about the costs or revenue changes associated with proposed legislation, a challenging enough task on its own. Sometimes, the CBO is asked to ...
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...
An experimental Metsera obesity drug led to an average 8.4% weight loss in a small clinical trial, preliminary results that keep the biotech competitive in the crowded mix of companies pursuing a ...
Zacks Investment Research on MSN
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
Roche RHHBY announced positive data from the late-stage lidERA Breast Cancer study on pipeline candidate giredestrant.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback